Original Research
Published on 23 Nov 2023
PAM variants in patients with thyrotrophinomas, cyclical Cushing’s disease and prolactinomas
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1305606
- 1,941 views
- 3 citations
Type at least 3 characters
436 articles
Articles
Review
Published on 21 Nov 2023
Vitex agnus castus effects on hyperprolactinaemia
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1269781
- 10,346 views
- 2 citations
Original Research
Published on 09 Nov 2023
The adult growth hormone multicentric retrospective observational study: a 24-month Italian experience of adherence monitoring via Easypod™ of recombinant growth hormone treatment in adult GH deficiency
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1298775
- 1,730 views
- 3 citations
Original Research
Published on 31 Oct 2023
Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1269787
- 2,378 views
- 2 citations
Original Research
Published on 31 Oct 2023
Interpetrosal sphingosine-1-phosphate ratio predicting Cushing’s disease tumor laterality and remission after surgery
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1238573
- 1,629 views
Review
Published on 25 Oct 2023
Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1266339
- 4,669 views
- 4 citations
Original Research
Published on 11 Oct 2023
Preoperative and postoperative blood testosterone levels in patients with acromegaly: a prospective study
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1259529
- 2,260 views
- 2 citations
Original Research
Published on 11 Oct 2023
The patient’s sex determines the hemodynamic profile in patients with Cushing disease
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1270455
- 1,455 views
- 1 citation
Clinical Trial
Published on 09 Oct 2023
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1165681
- 3,789 views
- 5 citations
Original Research
Published on 02 Oct 2023
The TRH test provides valuable information in the diagnosis of central hypothyroidism in patients with known pituitary disease and low T4 levels
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1226887
- 2,911 views
Original Research
Published on 27 Sep 2023
Strikingly low prevalence of pituitary incidentalomas in a teaching hospital in Uruguay
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1254180
- 1,390 views
Original Research
Published on 27 Sep 2023
Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1256975
- 1,694 views
- 1 citation
Original Research
Published on 26 Sep 2023
Intensity-modulated radiotherapy for cushing’s disease: single-center experience in 70 patients
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1241669
- 2,162 views
Original Research
Published on 31 Aug 2023
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1204206
- 3,096 views
- 4 citations
Original Research
Published on 29 Aug 2023
The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1242588
- 2,369 views
- 3 citations
Original Research
Published on 23 Aug 2023
Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension
in Pituitary Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2023.1236465
- 4,847 views
- 6 citations